Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Few data are available regarding the epidemiology of invasive aspergillosis (IA) in ICU patients. The aim of this study was to examine epidemiology and economic outcomes (length of stay, hospital costs) among ICU patients with IA who lack traditional risk factors for IA, such as cancer, transplants, neutropenia or HIV infection. METHODS: Retrospective cohort study using Premier Inc. Perspective™ US administrative hospital database (2005-2008). Adults with ICU stays and aspergillosis (ICD-9 117.3 plus 484.6) who received initial antifungal therapy (AF) in the ICU were included. Patients with traditional risk factors (cancer, transplant, neutropenia, HIV/AIDS) were excluded. The relationship of antifungal therapy and co-morbidities to economic outcomes were examined using Generalized linear models. RESULTS: From 6,424 aspergillosis patients in the database, 412 (6.4%) ICU patients with IA were identified. Mean age was 63.9 years and 53% were male. Frequent co-morbidities included steroid use (77%), acute respiratory failure (76%) and acute renal failure (41%). In-hospital mortality was 46%. The most frequently used AF was voriconazole (71% received at least once). Mean length of stay (LOS) was 26.9 days and mean total hospital cost was $76,235. Each 1 day lag before initiating AF therapy was associated with 1.28 days longer hospital stay and 3.5% increase in costs (p < 0.0001 for both). CONCLUSIONS: Invasive aspergillosis in ICU patients is associated with high mortality and hospital costs. Antifungal timing impacts economic outcomes. These findings underscore the importance of timely diagnosis, appropriate treatment, and consideration of Aspergillus as a potential etiology in ICU patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“For patient comorbidity, the Charlson Comorbidity Index (CCI) was calculated based on Deyo’s method using ICD-9 CM diagnosis codes [17,18].”
MethodVoriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationInvasive aspergillosis in critically ill patients without malignancy
Meersseman, W., Vandecasteele, S. J., Wilmer, A., Verbeken, E., Peetermans, W. E., & Van Wijngaerden, E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-093oc · Cited by 547
Invasive aspergillosis in the intensive care unit
Meersseman, W., Lagrou, K., Maertens, J., & Wijngaerden, E. V. (2007) · Clinical Infectious Diseases · doi:10.1086/518852 · Cited by 366
Cornillet, A., Camus, C., Nimubona, S., Gandemer, V., Tattevin, P., Belleguic, C., Chevrier, S., Meunier, C., Lebert, C., Aupee, M., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/505870 · Cited by 361
Kim, A., Nicolau, D. P., & Kuti, J. L. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01903.x · Cited by 60
Chang, D. C., Burwell, L. A., Lyon, G. M., Pappas, P. G., Chiller, T. M., Wannemuehler, K. A., Fridkin, S. K., & Park, B. J. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/524324 · Cited by 51 · cited 1×
“Nevertheless, as a recent validation study reported, specificity using ICD-9 codes for aspergillosis ranges from 28-88% [16].”
Background
Research works printed but not linked: 18
- Segal BH: Aspergillosis. N Engl J Med. 2009, 360 (18): 1870-1884. 10.1056/NEJMra0808853. · DOI · Paper page
- Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001, 32 (3): 358-366. 10.1086/318483. · DOI · Paper page
- Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, Girbes AR, Groeneveld AB: Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med. 2007, 33 (10): 1694-1703. 10.1007/s00134-007-0791-z. · DOI · Paper page
- Verweij PE, Denning DW: The challenge of invasive aspergillosis: increasing numbers in diverse patient groups. Int J Infect Dis. 1997, 2: 61-63. 10.1016/S1201-9712(97)90083-7. · DOI
- Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E: Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008, 177 (1): 27-34. · DOI · Paper page
- Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G: Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009, 66 (19): 1711-1717. 10.2146/ajhp080325. · DOI · Paper page
- Vandewoude KH, Blot SI, Benoit D, Colardyn F, Vogelaers D: Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect. 2004, 56 (4): 269-276. 10.1016/j.jhin.2004.01.006. · DOI
- Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F, Nolla-Salas J, Iruretagoyena JR, Barcenilla F: Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005, 9 (3): R191-199. 10.1186/cc3488. · DOI · Paper page
- Vandewoude K, Blot S, Benoit D, Depuydt P, Vogelaers D, Colardyn F: Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg. 2004, 59 (5): 251-257. · DOI · Paper page
- Stulberg JJ, Delaney CP, Neuhauser DV, Aron DC, Fu P, Koroukian SM: Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA. 2010, 303 (24): 2479-2485. 10.1001/jama.2010.841. · DOI · Paper page
- Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40 (5): 373-383. 10.1016/0021-9681(87)90171-8. · DOI · Paper page
- Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al: Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005, 9: r191-r199. 10.1186/cc3488. · DOI · Paper page
- Lortholary O, Charlemagne A, Bastides F, et al: A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998–1999. J Antimicrob Chemotherapy. 2004, 54: 456-64. 10.1093/jac/dkh348. · DOI
- Upton A, Kirby KA, Carpenter P, et al: Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortatliy. Clin Infect Dis. 2007, 44: 531-540. 10.1086/510592. · DOI · Paper page
- Auberger J, Lass-Flörl C, Ulmer H, Nogler-Semenitz E, Clausen J, et al: Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2008, 88 (5): 508-15. 10.1007/s12185-008-0184-2. · DOI
- Walsh TJ, Anaissie EJ, Denning DW, et al: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008, 46 (3): 327-60. 10.1086/525258. · DOI · Paper page
- MacKenzie EJ, Morris JA, Edelstein SL: Effect of pre-existing disease on length of hospital stay in trauma patients. J Trauma. 1989, 29 (6): 757-65. 10.1097/00005373-198906000-00011. · DOI · Paper page
- Siegel JH, Shafi S, Goodarzi S, Dischinger PC: A quantitative method for cost reimbursement and length of stay quality assurance in multiple trauma patients. J Trauma. 1994, 37 (6): 928-37. 10.1097/00005373-199412000-00010. · doi:10.1097/00005373-199412000-00010
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
The clinical spectrum of pulmonary aspergillosis
Kosmidis, C., & Denning, D. W. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206291 · Cited by 850
Estimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438
“Other studies of aspergillosis-related hospitalizations using administrative data found a median cost of $52 803 (inflation-adjusted to $74 653 in 2017 dollars) in 2006 [6] and a mean of $76 235 ($99 532 in 2017 dollars), specifically among intensive care unit patients during 2005–2008 [19], compared with a mean all-p…”
BackgroundTaccone, F. S., Van den Abeele, A.-M., Bulpa, P., Misset, B., Meersseman, W., Cardoso, T., Paiva, J.-A., Blasco-Navalpotro, M., De Laere, E., Dimopoulos, G., et al. (2015) · Critical Care · doi:10.1186/s13054-014-0722-7 · Cited by 405
The Changing Epidemiology of Invasive Fungal Infections
Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6515-1_2 · Cited by 370
Metadata
- Authors
- Baddley, J. W., Stephens, J. M., Ji, X., Gao, X., Schlamm, H. T., & Tarallo, M.
- Venue
- BMC Infectious Diseases
- Published
- 2013-01-23
- Volume
- 13
- Issue
- 1
- Pages
- 29-29
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W2067802940
- Cited by
- 145
- References
- 7
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/2.0 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. https://app.cochat.ai/papers/10.1186/1471-2334-13-29
- The paper
- Baddley, J. W., Stephens, J. M., Ji, X., Gao, X., Schlamm, H. T., & Tarallo, M. (2013). Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. BMC Infectious Diseases. https://doi.org/10.1186/1471-2334-13-29
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.